Licensing · MENA · Announced 30 Jul 2025
Althera Laboratories → Jamjoom Pharma
Licensing deal between Althera Laboratories (Ireland) and Jamjoom Pharma (Saudi Arabia), covering rosuvastatin + ezetimibe, announced 30 Jul 2025. Value: Undisclosed.
Parties: Althera Laboratories Limited (Ireland) → JAMJOOM PHARMACEUTICALS CO. (Saudi Arabia)
- Deal type
- Licensing
- Value
- Undisclosed
- Territory
- Saudi Arabia (exclusive) plus phased, non-exclusive expansion across other MEA markets
- Therapeutic area
- Cardiovascular
- Asset
- rosuvastatin + ezetimibe
- Announced
- 30 Jul 2025
Our analysis
Why this matters.
In July 2025, Ireland-based Althera Laboratories licensed Jamjoom Pharma to commercialize its fixed-dose, dual-action cholesterol-lowering combination — exclusively in Saudi Arabia and, non-exclusively, across other MEA markets, with a 2027 launch target.
The full analysis is free to read with a work email on this page.
Source: Jamjoom Pharma news